Drug intelligence / Profile preview

Adomelle

Development stage: Preclinical
Lead developer: Bromatech
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

Adomelle is a multi-strain probiotic dietary supplement marketed by the company Bromatech. [1] It contains a specific combination of live bacteria: *Lactobacillus plantarum* LP115, *Lactobacillus acidophilus* LA14, and *Bifidobacterium breve* B3. [2] This product is formulated to modulate the intestinal microbiota. It has been investigated in clinical studies for the management of obesity, where it was used alongside interventions like a hypocaloric diet. [5] Studies suggest it is effective in promoting weight loss, reducing abdominal fat, and improving metabolic markers by fostering an anti-obesogenic gut microbiome, including increasing beneficial bacteria such as *Akkermansia muciniphila*. [5]

Brand names: Adomelle
Other names: Lactobacillus plantarum LP115 + Lactobacillus acidophilus LA14 + Bifidobacterium breve B3

Beyond the preview

Go deeper on Adomelle.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adomelle.

Explore the full profile